Lead asset CT-01 on track for clinical trial application authorization in Q3 2023 Collaboration with Ono Pharmaceuticals in neurological diseases progressing according to planSolid cash position...
Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast
Captor Therapeutics Announces Three-Year Strategic Objectives
WROC?AW, Poland, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment for cancer and autoimmune diseases, reports its financial results for the third quarter of 2022 and provides a business update. The Company has made further substantial progress in the development of its lead programs throughout the period, most notably CT-01, with the selection of a drug candidate and the initiation of the necessary steps to generate the data required to commence clinical trials in patients. Following the reporting period, the Company has announced that it signed a drug discovery collaboration with Japanese pharmaceutical company Ono Pharmaceutical that could generate up to €197 million in an upfront payment, R&D funding and milestones, in addition to royalties on global sales.
WROC?AW, Poland, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE: CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announces a worldwide drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (Ono), to develop novel small molecule degrader drugs against a currently undrugged target of interest in neurodegenerative diseases.
Captor Therapeutics announces participation in upcoming scientific, investor, and partnering conferences in October 2022
Captor Therapeutics` first half of 2022 marked by significant progress in R&D and preparations for the commencement of clinical trials
Captor nominates the molecular glue CPT-6281 as drug candidate
Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate
Captor Therapeutics Selects CDMO for Clinical Trial Materials